High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy

Abstract

Background

Worldwide, frequent emergence of lamivudine (3TC)-resistant HBV mutants has been reported in HIV–HBV-coinfected patients during long-term antiretroviral therapy (ART) that contains 3TC as the sole anti-HBV drug. Three major patterns of mutations in HBV polymerase gene, namely single (rtM204V), double (rtL180M+rtM204V) and triple (rtV173L+rtL180M+rtM204V) mutations, are associated with 3TC-resistance; additionally, the triple mutation has vaccine-escape potential due to a corresponding change in overlapping surface gene. Data from India, a major reservoir for HIV and HBV infection, is lacking. Here we investigated the effect of long-term 3TC treatment on virological response for HBV and characterized the 3TC-resistant HBV mutations in a cohort of HIV–HBV-coinfected patients from eastern India.

Methods

A cross-sectional study was performed in HIV-infected patients (n=563) receiving 3TC-containing ART for ≥6 months from the major ART centre of eastern India during 2011–2012. The hepatitis B surface antigen-positive HIV-infected patients (n=62) were categorized into four groups with comparable sample size according to the 3TC exposure for ≥6–<12 months (group I; n=15), ≥12–<24 months (group II; n=20), ≥24–<48 months (group III; n=13) and ≥48 months (group IV; n=14). Patients’ plasma samples were examined for hepatitis B e antigen (HBeAg), HBV DNA, viral load and covalently closed circular DNA (cccDNA). HBV reverse transcriptase region was sequenced.

Results

With a longer period of 3TC exposure, the frequency of HIV–HBV-coinfected patients having HBV DNA suppression decreased. The prevalence of HBeAg-positivity, serum HBV DNA load >2,000 IU/ml and 3TC-resistant mutations simultaneously increased. Remarkably, the 3TC-resistant triple mutation predominated over the double mutation in this cohort (32.26% versus 19.34%) and prevailed in significantly higher frequency among HBV viraemic patients experiencing 3TC for ≥48 months (60% versus 10%; P=0.03). Patients with 3TC-resistant triple mutants had HBV genotype-D, high serum HBV DNA load and elevated alanine aminotransferase level, and presence of cccDNA in their serum.

Conclusions

Considering this alarmingly high incidence of 3TC-resistant triple mutation and its possible clinical/ public health implications, proper management of 3TC-resistance among HIV–HBV-coinfected patients is an urgent necessity in India.

References

Joshi

, O'Grady

, Dieterich

, Gazzard

, Agarwal

Increasing burden of liver disease in patients with HIV infection.

Lancet 2011; 377: 1198–1209.

Iser

D.M.

, Sasadeusz

J.J.

Current treatment of HIV/hepatitis B virus coinfection.

J Gastroenterol Hepatol 2008; 23: 699–706.

Benhamou

, Bochet

, Thibault

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Hepatology 1999; 30: 1302–1306.

Zoulim

, Locarnini

Hepatitis B virus resistance to nucleos(t)ide analogues.

Gastroenterology 2009; 137: 1593–1608.

Teo

C.G.

, Locarnini

S.A.

Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.

Antivir Ther 2010; 15: 445–449.

Saha

, Pal

, Biswas

Characterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern India.

PLoS ONE 2013; 8: e73613.

Iser

D.M.

, Lewin

S.R.

Future directions in the treatment of HIV-HBV coinfection.

HIV Ther 2009; 3: 405–415.

Gupta

, Singh

Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients.

World J Gastroenterol 2006; 12: 6879–6883.

Saravanan

, Velu

, Kumarasamy

Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India.

World J Gastroenterol 2007; 13: 5015–5020.

10.

Antiretroviral Therapy Guidelines for HIV-infected Adults and Adolescents May 2013. Department of AIDS Control, National AIDS Control Organisation Ministry of Health & Family Welfare Government of India. (Accessed 17 October 2014.) Available from http://www.naco.gov.in/upload/Policies%20&%20Guidelines/Antiretroviral%20Therapy%20Guidelines%20for%20HIV-Infected%20Adults%20and%20Adolescents.pdf.

11.

Pal A, Panigrahi R, Biswas A, et al.

Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients.

Virology 2013; 436: 134–142.

12.

Hall

T.A.

Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/ N T.

Nucleic Acids Symp Ser 1999; 41: 95–98.

13.

Geno2pheno[hbv]2.0 Max Planck Institute Informatik. (Accessed 10 October 2014.) Available from http://hbv.geno2pheno.org/index.php.

14.

Cabrerizo

, Bartolomé

, Caramelo

, Barril

, Carreno

Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases.

Hepatology 2000; 32: 116–123.

15.

Wai

C.T.

, Greenson

J.K.

, Fontana

R.J.

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Hepatology 2003; 38: 518–526.

16.

Sterling

R.K.

, Lissen

, Clumeck

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/ HCV coinfection.

Hepatology 2006; 43: 1317–1325.

17.

Dumea

, Streinu-Cercel

, Rugină

, Petcu

L.C.

, Cambrea

S.C.

Concordance between noninvasive assessments of fibrosis in patients with HIV/HIV+HBV infection. Proceedings of the 7th Romanian National HIV/ AIDS Congress and The 2nd Central European HIV Forum. 29–31 May 2014, Sibiu, Romania. Oral presentation 19.

18.

Soriano

, Puoti

, Peters

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

AIDS 2008; 22: 1399–1410.

19.

Gallego

, Sheldon

, García-Samaniego

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.

J Viral Hepat 2008; 15: 392–398.

20.

Matthews

G.V.

, Bartholomeusz

, Locarnini

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

AIDS 2006; 20: 863–870.

21.

Burnett

R.J.

, François

, Kew

M.C.

Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation.

Liver Int 2005; 25: 201–213.

22.

Bottecchia

, Souto

F.J.

, Ó

K.M.

Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.

BMC Microbiol 2008; 8: 11.

23.

Mendes-Correa

M.C.

, Pinho

J.R.R.

, Locarnini

High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.

J Med Virol 2010; 82: 1481–1488.

24.

Kouanfack

, Aghokeng

A.F.

, Mondain

A.M.

Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.

Antivir Ther 2012; 17: 321–326.

25.

Sheldon

, Ramos

, Garcia-Samaniego

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

J Acquir Immune Defic Syndr 2007; 46: 279–282.

26.

Ramos

, Núñez

, Martín-Carbonero

Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.

J Acquir Immune Defic Syndr 2007; 44: 557–561.

27.

Iacomi

, Vincenti

, Vairo

Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.

J Med Virol 2009; 81: 1151–1156.

28.

Taramasso

, Caligiuri

, Di Biagio

Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.

J Med Virol 2011; 83: 1905–1908.

29.

Thibault

, Gaudy-Graffin

, Colson

Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.

Virol J 2013; 10: 87.

30.

Hirsch

H.H.

, Kaufmann

, Sendi

, Battegay

Immune reconstitution in HIV-infected patients.

Clin Infect Dis 2004; 38: 1159–1166.

31.

Melegari

, Scaglioni

P.P.

, Wands

J.R.

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.

Hepatology 1998; 27: 628–633.

32.

Saha

, Pal

, Biswas

Molecular characterization of HBV strains circulating among the treatment-naive HIV/ HBV co-infected patients of eastern India.

PLoS ONE 2014; 9: e90432.

33.

Liaw

Y.F.

, Sung

J.J.

, Chow

W.C.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

N Engl J Med 2004; 351: 1521–1531.

34.

Bruno

, Sacchi

, Malfitano

, Filice

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.

Gastroenterology 2001; 121: 1027–1028.

35.

Levrero

, Pollicino

, Petersen

, Belloni

, Raimondo

, Dandri

Control of cccDNA function in hepatitis B virus infection.

J Hepatol 2009; 51: 581–592.

36.

Yokosuka

, Omata

, Imazeki

Hepatitis B virus RNA transcripts and DNA in chronic liver disease.

N Engl J Med 1986; 315: 1187–1192.

37.

Chen

, Sze

, He

M.L.

HBV cccDNA in patients’ sera as an indicator for HBV reactivation and an early signal of liver damage.

World J Gastroenterol 2004; 10: 82–85.

38.

Yuen

M.F.

, Wong

D.K.

, Sum

S.S.

Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.

Am J Gastroenterol 2005; 100: 1099–1103.

39.

Kuo

, Dienstag

J.L.

, Chung

R.T.

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

Clin Gastroenterol Hepatol 2004; 2: 266–272.

40.

Audsley

, Arrifin

, Yuen

L.K.

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

HIV Med 2009; 10: 229–235.

41.

Kim

H.N.

, Rodriguez

C.V.

, Van Rompaey

Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.

J Acquir Immune Defic Syndr 2014; 66: 96–101.